Dyspepsia Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Dyspepsia Drugs Market Analysis

The Dyspepsia Drugs Market size is estimated at USD 10.15 billion in 2024, and is expected to reach USD 12.63 billion by 2029, growing at a CAGR of 4.46% during the forecast period (2024-2029).

Dyspepsia or indigestion is characterized by pain or discomfort in the upper abdomen, commonly accompanied by nausea, bloating, belching, and sometimes vomiting. The primary driver for the market growth is the rising cases of indigestion or dyspepsia and growing awareness among people related to its treatment at an early stage to prevent severe gastrointestinal diseases, thereby propelling the market growth. For instance, as per a study published by Medicine Journal in October 2023,  the prevalence of functional dyspepsia (FD) was considerably higher in low- and middle-income countries, with 37.9%, compared to high-income countries at 10% in 2022. It further concluded that Sudan obtained the highest prevalence, 44.3%, then Egypt, 41.4%, while the lowest was in Algeria, 25.7%, in 2022. Thus, the high prevalence of dyspepsia among low-middle-income countries is anticipated to be a lucrative growth opportunity for dyspepsia treatment during the forecast period.

In addition, several studies emphasize that dyspepsia is the initial symptom of gastroesophageal reflux disease (GERD). For instance, according to a study published in the Journal of Gastroenterology and Hepatology in February 2024, it was concluded that 41.5% of GERD patients have symptoms of dyspepsia, and an overlap between GERD and non-diagnosed dyspepsia was found in 50% of GERD patients. Thus, the high burden of GERD indicates the high burden of untreated dyspepsia, which causes GERD in its later phase. Such studies highlight that as the GERD burden grows, so does the demand for dyspepsia drugs, contributing to market growth during the forecast period.

Also, poor lifestyle choices such as smoking and alcohol consumption lead to higher incidences of acidity and dyspepsia over time, which is expected to register significant growth during the forecast period. For instance, according to an article updated by the National Center for Biotechnology Information in May 2024, tobacco smoking is considered an etiological factor of reflux esophagitis or acid reflux, and it is regarded as a significant risk factor for acid reflux over the age of 50. Smoking causes functional abdominal pain and bloating, an essential symptom of dyspepsia. Therefore, smoking is associated with a high incidence of acidity, which is expected to boost the demand for dyspepsia drugs during the forecast period.

Additionally, the rising geriatric population is more prone to gastric indigestion problems, which are ultimately associated with dyspepsia. For instance, as per a study published by the Gastrointestinal Disorders Journal in March 2024, the estimated prevalence of dyspepsia in the elderly population ranges from 9% to 25%. Therefore, with the increasing geriatric population related to acid reflux diseases, the market is expected to experience growth during the forecast period.

Therefore, owing to factors such as poor lifestyle choices such as smoking and the increasing incidence of acidity, the market is expected to witness growth during the forecast period.

However, side effects associated with the dyspepsia drugs are expected to restrain the market's growth.

Dyspepsia Drugs Market Trends

The H2 Antagonist Segment is Expected to Witness Growth During the Forecast Period

Dyspepsia Drugs Industry Segmentation

As per the scope of the report, dyspepsia refers to indigestion or upset stomach that causes discomfort in the upper abdomen and leads to abdominal pain. Gastritis, peptic ulcers, gallstones, stomach cancer, constipation, and intestinal ischemia are gastrointestinal causes of dyspepsia. Diabetes, thyroid disorders, kidney problems, and the use of nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen) are examples of non-gastrointestinal causes. The dyspepsia drug market is segmented by drug class into antacids, proton pump inhibitors, H2 antagonists, antibiotics, and other drug classes. By route of administration, the market is segmented into oral and injectable. By distribution channel, the market is segmented into online pharmacy, retail pharmacy, and other distribution. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also offers the market size and forecasts for 17 countries across the region. The report offers the value (USD) for the above segments.